Daniel Petrylak, MD

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the IMvigor Study, which looked at anti PD-1 agent atezolizumab in advanced urothelial carcinoma.

The study evaluated atezolizumab given every three weeks at 1,200 mg. It also investigated the role of PD-L1 expression in the tumor immune cells, says Petrylak. It was determined that there was a better response rate in patients who were strong expressers of PD-L1 in the immune cells.

Previous trials have shown that there is no correlation between tumor cell expression of PD-L1 and outcome with anti PD-1 agents, explains Petrylak. However, when looking at just the immune cells, a positive relationship between PD-L1 expression and improved outcome with anti PD-1 agents was found.

Videos

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center discusses the IMvigor Study, which looked at anti PD-1 agent atezolizumab in advanced urothelial carcinoma.

Dr. Daniel Petrylak on the IMvigor Study of Atezolizumab in Advanced Bladder Cancer

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses a phase Ia study examining atezolizumab in patients with urothelial bladder cancer. 

Daniel Petrylak, MD | Authors

Articles

Dr. Daniel Petrylak on the IMvigor Study of Atezolizumab in Advanced Bladder Cancer

Phase IA Study of Atezolizumab in Urothelial Bladder Cancer